OS Therapies (NYSEAMERICAN:OSTX) Stock Rating Upgraded by Roth Capital

OS Therapies (NYSEAMERICAN:OSTX) was upgraded by research analysts at Roth Capital to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

OSTX has been the topic of several other reports. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 4th. Lake Street Capital reduced their price objective on OS Therapies from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research report on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $13.33.

OS Therapies Stock Performance

Shares of NYSEAMERICAN OSTX opened at $1.72 on Thursday. The stock has a market cap of $76.61 million, a PE ratio of -1.59 and a beta of -0.83. OS Therapies has a fifty-two week low of $1.15 and a fifty-two week high of $2.57. The stock has a fifty day moving average of $1.79 and a 200-day moving average of $1.55.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings data on Monday, May 18th. The company reported ($0.27) EPS for the quarter. On average, sell-side analysts predict that OS Therapies will post -0.84 EPS for the current year.

Institutional Trading of OS Therapies

A number of institutional investors have recently modified their holdings of the company. State Street Corp grew its stake in shares of OS Therapies by 16.3% in the fourth quarter. State Street Corp now owns 58,500 shares of the company’s stock worth $82,000 after purchasing an additional 8,200 shares during the last quarter. Jane Street Group LLC bought a new position in OS Therapies during the 4th quarter valued at approximately $39,000. Geode Capital Management LLC lifted its holdings in OS Therapies by 31.1% in the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after buying an additional 58,350 shares during the period. Susquehanna International Group LLP purchased a new stake in OS Therapies in the 3rd quarter worth approximately $29,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of OS Therapies in the 3rd quarter worth approximately $40,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.